1月6日 - ** 药物开发商Genprex GNPX.O股价盘前上涨7.8%至1.94美元
** 该公司称，其试验性糖尿病基因疗法 GPX-002 在早期动物实验中取得了令人鼓舞的结果
** 该疗法改善了糖的处理；研究中一种灵长类动物的血糖在 7 个月后恢复正常，另一种灵长类动物的血糖有所改善，但没有完全恢复正常
** 小鼠在 4 周内血糖恢复正常 - GNPX
** 公司计划开展更多动物实验，并争取监管机构批准进行人体试验
** 截至上次收盘，股价在过去一年中上涨了 ~3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.